Seattle Genetics Strikes Again with $208M ADC Deal with Abbott

Seattle Genetics has racked up another collaboration agreement  which involves closely-watched antibody-drug conjugate technology. The red-hot ADC company is pocketing $8 million from Abbott Laboratories, which is promising up to $200 million more as it focuses on a single cancer target.

"This is the second ADC collaboration with a multinational pharmaceutical company that we have announced this year, further illustrating the important role that our ADC technology is poised to play in the treatment of many types of cancer," says Eric Dobmeier, the chie